

Amended B1
[by] polydeoxyribonucleotides having a molecular weight in the range 7,000-60,000 Da, [preferably 10,000-60,000 Da, obtainable] obtained by depolymerization of nucleic acids, wherein the polydeoxyribonucleotides are located on the outer surface of the liposome [, for use as a medicament].

Claims 2-5, line 1 of each, delete "Complexes" and substitute therefor --The pharmaceutical formulation-- and delete "for preparing medicaments".

Claims 6 and 7, line 1 of each, delete "Complexes" and substitute therefor --The pharmaceutical formulation--.

B2
8. (Twice Amended) The pharmaceutical formulation [Complexes] according to claim 1 wherein one or more antioxidants [preferably alphotocopherol] are added.

Claim 9, line 1, delete "Complexes" and substitute therefor --The pharmaceutical formulation--; and
lines 6-8, delete ", preferably said cationic surfactants are quaternary ammonium surfactants having aliphatic chains with 18 carbon atoms".

Claim 10, line 1, delete "Complexes" and substitute therefor --The pharmaceutical formulation--;

line 2, delete "lipid/s" and substitute therefor --lipid(s)--; and
lines 3-4, delete ", preferably being 10:1".

B³
11. (Once Amended) The pharmaceutical formulation [Complexes] according to
claim 10 wherein the phospholipids in the liposomes include [, together with the]
phosphatidylcoline [(] or phosphatidylethanolamine [) there is] and a second and
different lipid and the molar ratio of the phosphatidylcoline [(] or
phosphatidylethanolamine [)] : second lipid : surfactant ranges from 9:1:0.05 to 7:3:3 [,
preferably 8:2:1].


Claim 12, line 1, delete "Complexes" and substitute therefor --The
pharmaceutical formulation--; and
lines 3-4, delete ", preferably is 10:1".

Please cancel claims 13-18 without prejudice or disclaimer.

Please add the following new claims.

B⁴
--19. A method for treating inflammation in a patient in need thereof,
comprising administering to the patient an antiinflammatory effective amount of the
pharmaceutical formulation according to claim 1.

20. A method for treating thrombosis in a patient in need thereof, comprising administering to the patient an antithrombotic effective amount of the pharmaceutical formulation according to claim 1.



21. A method for treating hypertension in a patient in need thereof, comprising administering to the patient an antihypertensive effective amount of the pharmaceutical formulation according to claim 1.

22. A method for providing a sustained release of endothelial prostacyclin in a patient in need thereof, comprising administering to the patient a sustained release providing effective amount of the pharmaceutical formulation according to claim 1.--

REMARKS

Claims 1-18 are currently pending. In this Response, applicants have amended claims 1-12, canceled claims 13-18, and added new claims 19-22. Claims 1-12 and 19-22 are presented for reconsideration.

Claims 1-18 are rejected under 35 USC §112, second paragraph, as being indefinite. In addition, claims 15-18 are rejected under 35 USC §101, because these claims are improper "use" claims.